

Chimerix Inc

COMPANY AND PIPELINE OVERVIEW REPORT

Coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 12-Apr-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drugs..... 10

[Return to Table of Contents](#)

Chimerix Inc

COMPANY OVERVIEW

Company Name	Chimerix Inc
Parent Company Name	Chimerix Inc
Website	http://www.chimerix.com/
Country	US
Number of Drugs in Active Development	6
Number of Inactive Drugs	5
Number of Patents as Owner	16
Number of Patents as Third Party	1
Number of Deals	9
Key Indications	Cytomegalovirus infection,Adenovirus infection,BK virus infection,Influenza virus infection,Polyomavirus infection,DNA virus infection,Dengue virus infection,Hepatitis,Mycobacterium tuberculosis infection,Plasmodium infection,Variola virus infection
Key Target-based Actions	Hepatitis C virus NS5B polymerase inhibitor,Cytochrome P450 reductase inhibitor,P-Glycoprotein inhibitor,Acetaldehyde dehydrogenase stimulator,B-lymphocyte antigen CD20 stimulator,BCL2 gene inhibitor,Cytosine deaminase stimulator,Glutathione S-transferase stimulator,Homeobox protein NANOG stimulator,Integrin alpha-4/beta-1 antagonist,P-Glycoprotein 3 stimulator,POU domain 5 transcription factor 1 stimulator,SOX transcription factor 2 stimulator
Key Technologies	Small molecule therapeutic,Oral formulation,Parenteral formulation unspecified,Lipid,Prodrug,Nucleotide and derivatives,Oral sustained release formulation,Drug combination,Adult stem cell therapy,Antibody,Chemical purification,Condensational synthesis,Crystalline form,Dermatological formulation,Drug implant,Embryonic stem cell therapy,Hydrolytic synthesis,Oligonucleotide,Ophthalmic gel formulation,Pluripotent stem cell therapy,Salt synthesis

COMPANY PROFILE

SUMMARY

Chimerix Inc began operations in the third quarter of 2002, to commercialize the proprietary chemistry developed in the laboratory of Dr Karl Hostetler at the University of California San Diego and the Veterans Administration Hospital in San Diego, CA. The company uses its proprietary lipid conjugate technology to enhance the oral availability and delivery of antiviral drugs to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Chimerix intends to develop drug candidates through proof-of-concept clinical trials before seeking to outlicense clinical candidates to pharmaceutical companies for late stage clinical trials, distribution, and marketing.

LICENSING AGREEMENTS

In May 2006, Chimerix acquired Dr Leroy Townsend's chemical lead antiviral and oncology compound library from the University of Michigan. The company would add promising compounds to its technology platform, or license them to other pharmaceutical and biotechnology companies.

EARLY R&D

By May 2010, the company was also investigating compounds for malaria and dengue fever.

By August 2009, the company was investigating hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza programs.

By May 2004, Chimerix was using its technology to create drug candidates for hepatitis C virus infection from known inhibitors of the viral polymerase.

FINANCIAL

[Return to Table of Contents](#)



In March 2013, Chimerix filed a Form S-1 with the US SEC for a proposed IPO of its common stock.

In February 2011, the company raised \$45 million from the closing of a series F financing.

In August 2009, Chimerix raised \$16.1 million from the closing of a series E financing.

In February 2007, Chimerix raised \$23.1 million from the private placement of series D preferred stock.

In November 2004, Chimerix raised \$11 million private placement of its series C preferred stock. The funds would augment a grant from the NIH for \$36.1 million awarded to Chimerix for the development of CMX-001 and would allow the company to accelerate its cytomegalovirus infection, multi-drug resistant HIV-1 infection and viral hepatitis programs.


In September 2003, Chimerix closed a \$3.1 million preferred stock private financing. The funds were to be used to support Chimerix's drug development programs for HIV and HCV, and to continue to support the company's R&D activities.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



Drugs by Indication Table


Indication	Active	Inactive	Total
Infectious disease	5	5	10
Respiratory disease	2	1	3
Gastrointestinal disease	1	2	3

[Return to Table of Contents](#)

Inflammatory disease	1	2	3
----------------------	---	---	---

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	5
Discontinued	1
No Development Reported	4

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	1	0	1	0	2
Drug - Screening/Evaluation	1	0	0	0	1
Drug - Early Research/Development	1	0	0	0	1
Drug - Funding	3	0	0	0	3
Drug - Asset Divestment	0	0	1	0	1
Drug - CRADA	1	0	0	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	1	10
Inflammatory disease	0	1
Gastrointestinal disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 3	1	1
Phase 2	0	3
Phase 1	0	5
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)



PATENTS *

Indication	As Owner	As Third Party	Total
Cardiovascular disease	0	1	1
Endocrine disease	2	1	3
Gastrointestinal disease	6	1	7
Genitourinary disease	3	0	3
Hematological disease	2	1	3
Degeneration	1	0	1
Andrology	2	0	2
Immune disorder	3	1	4
Musculoskeletal disease	1	0	1
Neoplasm	3	1	4
Ocular disease	1	0	1
Metabolic disorder	0	1	1
Neurological disease	1	1	2
Respiratory disease	3	0	3
Infectious disease	17	0	17
Inflammatory disease	6	0	6
Fatigue	1	0	1
Gynecology and obstetrics	1	0	1
Surgical procedure	0	1	1

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

CMX-001

Drug Name	CMX-001
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Phase 2 Clinical
Active Indications	DNA virus infection, Cytomegalovirus infection, Variola virus infection, BK virus infection, Polyomavirus infection, Adenovirus infection
Target-based Actions	
Other Actions	Synergist, Viral replication inhibitor
Technologies	Lipid, Oral formulation, Small molecule therapeutic
Last Change Date	29-Mar-2013

antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix

Drug Name	antimalarial compounds, iThemba Pharmaceuticals/Medicines For Malaria Venture/Chimerix
Key Synonyms	
Originator Company	iThemba Pharmaceuticals Pty Ltd
Active Companies	iThemba Pharmaceuticals Pty Ltd, Chimerix Inc
Inactive Companies	Medicines for Malaria Venture
Highest Status	Discovery
Active Indications	Plasmodium infection
Target-based Actions	
Other Actions	Antiparasitic, Unspecified drug target
Technologies	Small molecule therapeutic
Last Change Date	08-Mar-2013

[Return to Table of Contents](#)



nucleoside analogs (hepatitis C virus infection), Chimerix

Drug Name	nucleoside analogs (hepatitis C virus infection), Chimerix
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hepatitis
Target-based Actions	Hepatitis C virus NS5B polymerase inhibitor
Other Actions	Antiviral
Technologies	Nucleotide and derivatives, Small molecule therapeutic
Last Change Date	07-Mar-2013

influenza A and B virus targeting compounds, Chimerix

Drug Name	influenza A and B virus targeting compounds, Chimerix
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Influenza virus infection
Target-based Actions	
Other Actions	Unspecified drug target, Antiviral
Technologies	Small molecule therapeutic, Parenteral formulation unspecified
Last Change Date	12-Mar-2013

[Return to Table of Contents](#)

dengue virus targeting compounds, Chimerix

Drug Name	dengue virus targeting compounds, Chimerix
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Dengue virus infection
Target-based Actions	
Other Actions	Antiviral, Unspecified drug target
Technologies	Small molecule therapeutic, Parenteral formulation unspecified
Last Change Date	12-Mar-2013

Mycobacterium tuberculosis infection targeting compounds, Chimerix

Drug Name	Mycobacterium tuberculosis infection targeting compounds, Chimerix
Key Synonyms	
Originator Company	Chimerix Inc
Active Companies	Chimerix Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Mycobacterium tuberculosis infection
Target-based Actions	
Other Actions	Unspecified drug target, Antibacterial
Technologies	Small molecule therapeutic
Last Change Date	11-Mar-2013

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

